BioClinica Partners with Axio Research Corporation and Beardsworth Consulting Group

BioClinica Partners with Axio Research Corporation and Beardsworth Consulting Group
New CRO Partners Match Quality of Certified Partner Program
 

NEWTOWN, Pa., Aug 10, 2010 (BUSINESS WIRE) -- BioClinica(TM), Inc., a global provider of clinical trial management services, today announced it has created strategic partnerships with two privately held clinical research organizations (CROs), Axio Research Corporation and Beardsworth Consulting Group, Inc. Both alliances strengthen the BioClinica Certified Partner Program and provide customers with additional support in complex therapeutic areas of study and data monitoring and management.

Mark Weinstein, CEO of BioClinica, Inc. "Both Axio Research and Beardsworth match the quality and industry leadership of all partners recognized by the BioClinica Certified Partner Program, and we are pleased to offer our customers this expanded support. Our certified partners now represent a collective experience of over 1000 trials in more than 6,000 sites across 52 countries."

Since 1979, Axio Research has provided high-quality data management, statistical and medical writing services for industry, government, and academic sponsors in the clinical research field. Based in Seattle, Washington, Axio has participated in more than 400 industry-based clinical trials. The company also provides clinical trial design and clinical events committee support services, and serves as the independent statistical center for Data Monitoring Committees.

Based in Flemington, New Jersey, Beardsworth is a specialty CRO in Oncology, delivering a broad range of clinical research services to pharmaceutical and biotechnology companies. Since 1986, the company has focused on complicated trials in complex therapeutic areas, utilizing an internal paper-based data management system. Michael O'Brien, CEO of Beardsworth states, "There has been an increasing demand from our oncology clients for an EDC platform that is focused on the particular needs of oncology studies. BioClinica's commitment to, and understanding of this complex therapeutic area were some of the key reasons we selected them as our partner." Beardsworth is a WBENC (Women's Business Enterprise National Council)-certified, woman-owned business and registrant with CCR (Central Contractor Registration).

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at http://twitter.com/bioclinica.

About BioClinica

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management services. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, and clinical supply chain design and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With more than 20 years of experience and over 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.